Acute Right Ventricular Failure in Cardiac Surgery During Cardiopulmonary Bypass Separation: A Retrospective Case Series of 12 Years' Experience With Intratracheal Milrinone Administration.


Journal

Journal of cardiothoracic and vascular anesthesia
ISSN: 1532-8422
Titre abrégé: J Cardiothorac Vasc Anesth
Pays: United States
ID NLM: 9110208

Informations de publication

Date de publication:
03 2019
Historique:
received: 12 04 2018
pubmed: 27 1 2019
medline: 8 6 2019
entrez: 27 1 2019
Statut: ppublish

Résumé

To report the authors' 12 years of experience with intratracheal milrinone administration and to assess the efficacy and limitations of intratracheal milrinone bolus administration for the treatment of unexpected acute right ventricular (RV) failure in patients undergoing cardiac surgery. Retrospective analysis. Single-center university hospital. One hundred seventy-six patients (4.6%) undergoing on-pump cardiac surgery. Endotracheal tube administration of milrinone (5-mg bolus) after unexpected acute RV failure during separation from cardiopulmonary bypass (CPB) weaning. RV failure was defined as the simultaneous presence of all of the following criteria: (1) hemodynamic instability or difficult separation from CPB with associated elevated central venous pressure or abnormal RV pressure waveform, (2) >20% reduction of RV fractional area change from baseline evaluated by transesophageal echocardiography, and (3) anatomical visualization of impaired or absent RV wall motion by direct intraoperative visual inspection. Intratracheal milrinone administration was found to improve RV failure in 109 patients (61.9%) whereas RV failure persisted in 67 patients (38.1%). Using a multiple logistic regression model, severely decreased left ventricular ejection fraction (<35% v >50%) (adjusted odds ratio [OR] 3.72; 95% confidence interval [CI] 1.2-11.3; p = 0.012), longer CPB time (adjusted OR 1.014; CI 1.01-1.02; p = 0.001) and elevated postoperative fluid balance (adjusted OR 1.39; CI 1.1-1.8; p = 0.02) were found to be significant predictors of persistent RV failure. Intratracheal instillation of milrinone was associated with clinical improvement of RV failure occurring during separation from CPB in almost two-thirds of patients. Factors limiting its therapeutic efficacy include severe left ventricular dysfunction, increased fluid balance, and long CPB time.

Identifiants

pubmed: 30683595
pii: S1053-0770(18)30895-4
doi: 10.1053/j.jvca.2018.09.016
pii:
doi:

Substances chimiques

Cardiotonic Agents 0
Milrinone JU9YAX04C7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

651-660

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Caroline E Gebhard (CE)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada; Department of Anesthesiology and Intensive Care Medicine, University Hospital Basel, Basel, Switzerland.

Antoine Rochon (A)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Jennifer Cogan (J)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Hosham Ased (H)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada; Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Georges Desjardins (G)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Alain Deschamps (A)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Paul Gavra (P)

Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.

Jean-Sebastien Lebon (JS)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Pierre Couture (P)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Christian Ayoub (C)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Sylvie Levesque (S)

Montreal Health Innovations Coordinating Centre, Montreal Heart Institute, Montreal, Quebec, Canada.

Mahsa Elmi-Sarabi (M)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada; Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Etienne J Couture (EJ)

Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

André Y Denault (AY)

Research Centre, Montreal Heart Institute, Montreal, Quebec, Canada; Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada. Electronic address: andre.denault@umontreal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH